Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Insider Sells $76,296.00 in Stock

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) insider Aradhana Sarin sold 578 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $132.00, for a total transaction of $76,296.00. Following the transaction, the insider now owns 30,201 shares in the company, valued at approximately $3,986,532. The sale was disclosed in a filing with the SEC, which is available at this link.

NASDAQ:ALXN opened at $125.34 on Thursday. The stock has a 50-day simple moving average of $124.39. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $28.06 billion, a P/E ratio of 17.68, a P/E/G ratio of 0.94 and a beta of 1.58. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.99 by $0.40. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period last year, the firm posted $1.68 earnings per share. As a group, analysts expect that Alexion Pharmaceuticals, Inc. will post 8.61 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. FMR LLC lifted its stake in shares of Alexion Pharmaceuticals by 10.4% in the first quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock worth $3,939,729,000 after buying an additional 2,746,055 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of Alexion Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after buying an additional 192,857 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of Alexion Pharmaceuticals by 17.3% in the first quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after buying an additional 1,512,545 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of Alexion Pharmaceuticals by 12.9% in the first quarter. Clearbridge Investments LLC now owns 5,810,033 shares of the biopharmaceutical company’s stock worth $785,400,000 after buying an additional 665,574 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its stake in shares of Alexion Pharmaceuticals by 220.9% in the first quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after buying an additional 2,924,550 shares in the last quarter. 94.42% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have issued reports on the stock. Raymond James assumed coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, April 10th. They set an “outperform” rating and a $161.00 price target on the stock. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Royal Bank of Canada restated an “outperform” rating and set a $186.00 price target (up previously from $165.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 27th. Cowen restated a “buy” rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 13th. Finally, TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research note on Thursday, April 25th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $161.06.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Read More: Trading Ex-Dividend

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.